A Mayo Clinic researcher is the first to develop a series of three-dimensional (3D) models of an enzyme responsible for the replication of the deadly SARS (Severe Acute Respiratory syndrome) virus. These instantaneous “structures-in-time” are central to designing an anti-SARS drug -- and are therefore a welcome advance as the virus continues to threaten public health.
